Cts Coupe White Diamond Tan Leather Low Miles Finance Performance on 2040-cars

Auto blog

GM recalling 117,000 sedans, crossovers, SUVs, pickups and vans

General Motors has issued a stop-sale to dealers and has notified the National Highway Transportation Safety Administration of its intention to recall 117,000 vehicles in the United States, Canada and Mexico. Of those vehicles, only 4,500 are at dealerships.
The affected vehicles include the Cadillac CTS and Chevrolet Impala sedans, fullsize SUVs (Cadillac Escalade, Chevy Tahoe and Suburban and GMC Yukon and Yukon XL), Lambda-platform crossovers (Chevy Traverse, Buick Enclave and GMC Acadia), heavy-duty pickups (Chevy Silverado HD and GMC Sierra HD) and fullsize vans (Chevy Express and GMC Savana). The sedans and body-on-frame SUVs include model years 2013 and 2014, while the CUVs, heavy-duty pickups and vans are limited to MY2014.
GM confirmed the recall to Autoblog via an emailed statement (which we've included below). According to the statement, the issue at hand in what is the company's 69th recall of 2014 covers the chassis-control module. Automotive News is reporting that a problem in the chassis-control system could cause a short in the module, which could cause the engine to stall or fail to start. The fault could also affect the trailer-brake control, provided it's equipped.

Cadillac ATS failing to command BMW 3 Series-like pricing as hoped

The BMW 3 Series has long been the benchmark for small and sporty luxury vehicles, but the Cadillac ATS has come on strong in its short time on the market as a true rival in this segment. As impressive as Cadillac's new compact sedan is, however, Automotive News is reporting that the car is still lagging behind the 3 Series when it comes to actual transaction pricing.
According to the article, the average transaction price for the ATS is $39,459 while the 3 Series is at a much larger $44,764, but, just as importantly, Cadillac has about $500 more in incentives on the ATS compared to BMW. Transaction prices are much closer to cars like the Mercedes C-Class and Audi A4. Of course, this is all with the ATS trying to take on its small,sport sedan rivals with a single bodystyle and limited powertrain options compared to the numerous options available from the German automakers in this class.
This uneven battle won't last long, though, as recent spy shots have revealed that Cadillac is hard at work on a high-performance ATS-V and an ATS Coupe. No official word as to when either of these models will be unveiled, but with auto show season set to kick off, we're expecting sooner rather than later. The best news for the ATS is that the Automotive News says sales of the ATS are on target and that 74 percent of ATS buyers are new to Cadillac - two important factors for the brand as it tries to break into this tough segment.

2013 Cadillac XTS [w/video]

The Cadillac Of Stopgaps
As confusing as most alphanumeric car names have gotten in recent years, at least one constant has been that the letter "X" is generally indicative of a crossover. Then why did General Motors use this letter on its new 2013 Cadillac XTS luxury sedan? Well, for that, we'll have to look to the world of mathematics where "X" stands for an unknown variable or a placeholder. Now we're talking. The XTS is just an interim product sitting at the top of Cadillac's four-door food chain until the brand gets a true flagship in place. That sounds like a lot of resources to spend on what will likely be a one-and-done model, but the automaker needed to get something - anything - to replace the DTS.
So here you have the 2013 XTS. A big luxury sedan that was created to bridge the gap between Cadillac's recent past and its pending future. Going into our week with this XTS knowing that it was a stopgap measure proved to be both a blessing and a curse. On one hand, we know (or hope) that this car will act as a baseline for future high-end Cadillac models, but at the same time, we couldn't help but be mindful of past stopgap models, albeit in more entry-level segments, like the Cimarron and Catera.